Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA.

ABSTRACT: Cell-free DNA (cfDNA) next-generation sequencing is a noninvasive approach for genomic testing. We report the frequency of identifying alterations and their clinical actionability in patients with advanced/metastatic cancer. Prospectively consented patients had cfDNA testing performed. Alterations were assessed for therapeutic implications. We enrolled 575 patients with 37 tumor types. Of these patients, 438 (76.2%) had at least one alteration detected, and 205 (35.7%) had one or more alterations of high potential for clinical action. In diseases with 10 or more patients enrolled, 50% or more had at least one alteration deemed of high potential for clinical action. Trials were identified in 80% of patients (286 of 357) with any alteration and in 92% of patients (188 of 205) with one or mor

SUBMITTER: Sanchez NS 

PROVIDER: S-EPMC7448805 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature